DMG Media

SHUTTERSTOCK JOINS THE BOARD OF THE NEWS MEDIA COALITION

Retrieved on: 
Thursday, July 7, 2022
Organic, Music, Academy Awards, Freedom, Associated Press, Screen Actors Guild Awards, Publishing Council of the Moscow Patriarchate, Deutsche Presse-Agentur, Seoul Music Awards, Collection, 3D, Agence France-Presse, NMC, Guardian Media Group, Ownership, Company, DMG Media, Australian Associated Press, News Corp Australia, Stuff, Thomson Reuters, Industry, TurboSquid, News UK, Getty Images, Policy, News media, BAFTA, Public policy, Sport, NYSE, News Media Coalition, SNTV, PA Media, Editorial, PicMonkey, News, Newsroom, NEW, 1st Screen Actors Guild Awards, Splash News, Telegraph Media Group, English, Mark (given name), AP, Publishing, Public relations, Video game, Bigstock, Shutterstock

NEW YORK, July 7, 2022 /PRNewswire/ -- Shutterstock, Inc. (NYSE: SSTK), a leading global creative platform offering full-service solutions, high-quality content, and creative workflow solutions for brands, businesses and media companies, today announced that it has joined the News Media Coalition (NMC), an international industry organization comprising global news brands, including major news publishers and news agencies. The NMC's mission is to safeguard independent news-gathering opportunities, ensuring legal intellectual property rights are respected, as well as negotiate best practice arrangements for members' news operations and content freedoms. 

Key Points: 
  • Shutterstock Editorial is committed to supporting a free press that allows journalists and contributors to report editorially on events around the world without arbitrary restriction.
  • Andrew Moger, Chief Executive Officer at News Media Coalition, said: "The NMC is the only international news industry body operating in this area.
  • Shutterstock joins our board at a time when a free press is more important than ever.
  • Shutterstock, Inc. (NYSE: SSTK ), is the leading global creative platform for transformative brands and media companies.

SHUTTERSTOCK JOINS THE BOARD OF THE NEWS MEDIA COALITION

Retrieved on: 
Thursday, July 7, 2022
Organic, Music, Academy Awards, Freedom, Associated Press, Screen Actors Guild Awards, Publishing Council of the Moscow Patriarchate, Deutsche Presse-Agentur, Seoul Music Awards, Collection, 3D, Agence France-Presse, NMC, Guardian Media Group, Ownership, Company, DMG Media, Australian Associated Press, News Corp Australia, Stuff, Thomson Reuters, Industry, TurboSquid, News UK, Getty Images, Policy, News media, BAFTA, Public policy, Sport, NYSE, News Media Coalition, SNTV, PA Media, Editorial, PicMonkey, News, Newsroom, NEW, 1st Screen Actors Guild Awards, Splash News, Telegraph Media Group, English, Mark (given name), AP, Publishing, Public relations, Video game, Bigstock, Shutterstock

NEW YORK, July 7, 2022 /PRNewswire/ -- Shutterstock, Inc. (NYSE: SSTK), a leading global creative platform offering full-service solutions, high-quality content, and creative workflow solutions for brands, businesses and media companies, today announced that it has joined the News Media Coalition (NMC), an international industry organization comprising global news brands, including major news publishers and news agencies. The NMC's mission is to safeguard independent news-gathering opportunities, ensuring legal intellectual property rights are respected, as well as negotiate best practice arrangements for members' news operations and content freedoms. 

Key Points: 
  • Shutterstock Editorial is committed to supporting a free press that allows journalists and contributors to report editorially on events around the world without arbitrary restriction.
  • Andrew Moger, Chief Executive Officer at News Media Coalition, said: "The NMC is the only international news industry body operating in this area.
  • Shutterstock joins our board at a time when a free press is more important than ever.
  • Shutterstock, Inc. (NYSE: SSTK ), is the leading global creative platform for transformative brands and media companies.

US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

Retrieved on: 
Wednesday, July 6, 2022
Review, FDA, Annual report, ODD, PNOC, Patient, Brain tumor, PRV, Food and Drug Administration Safety and Innovation Act, ASX, Marketing, PI3K, American Association for Cancer Research, Goal, VEGFR3, V6 PRV engine, DMG Media, AACR, Innovation Act, Glioblastoma, Orphan, Food, AT/RT, American Association, St. Jude Children's Research Hospital, SEC, Incidence, Rinderpest, NASDAQ, Acceleration, Twitter, Brain, Neurodevelopmental disorder, Program, Multimedia, KZIA, GBM, Pharmaceutical industry, Vaccine, Genentech, Kazia Pelka, DIPG

Rare Pediatric Disease Designation (RPDD) is granted to drugs which are under development for rare childhood diseases.

Key Points: 
  • Rare Pediatric Disease Designation (RPDD) is granted to drugs which are under development for rare childhood diseases.
  • Paxalisib was previously granted orphan drug designation (ODD) for AT/RT by FDA on 16 June 2022.
  • Brain cancer is the most common cause of cancer death in children, and outcomes in many forms of childhood brain cancer have not improved in decades.
  • In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for AT/RT in June 2022.

US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

Retrieved on: 
Friday, June 17, 2022
KZIA, FDA, St. Jude Children's Research Hospital, Johns Hopkins School of Medicine, ASX, VEGFR3, ODD, PDUFA, ODE, Orphan, Marketing, Prescription Drug User Fee Act, RT, NASDAQ, AACR, Glioma, Brain, AT/RT, DMG Media, Twitter, Adult, PI3K, Diffuse intrinsic pontine glioma, Patient, GBM, Multimedia, PNOC, Therapy, Life, Pharmaceutical industry, Medical imaging, Kazia Pelka, Glioblastoma, Genentech, DIPG

Kazia CEO, Dr James Garner, commented, "childhood brain cancer has emerged as an important area of focus for the paxalisib program.

Key Points: 
  • Kazia CEO, Dr James Garner, commented, "childhood brain cancer has emerged as an important area of focus for the paxalisib program.
  • Kazia Therapeutics will participate in a webinar to discuss the company's activities in childhood brain cancer on Wednesday 22ndJune 2022.
  • Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020.
  • In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and Orphan Designation for AT/RT in June 2022.

POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING

Retrieved on: 
Monday, June 13, 2022
University, KZIA, Prognosis, Goal, Time, US, Research, AACR, Safety, Survival, Associate, PI3K, Johns Hopkins University, Annual report, VEGFR3, PNOC, Brain, Disease, Orphan, Glioblastoma, ET, American Association for Cancer Research, Hope, GBM, Multimedia, American Association, DMG Media, ONC201, FDA, Patient, International Symposium on Endovascular Therapy, Mouse, NASDAQ, Poster, Hunter Medical Research Institute, Twitter, SEC, Life expectancy, Diffuse intrinsic pontine glioma, Diagnosis, Clinical trial, ASX, DRD2, Death, Cancer, Pharmaceutical industry, Medicine, Medical imaging, Medical device, Genentech, DIPG, Kazia Pelka

The data is the subject of two poster presentations at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO), held in Hamburg, Germany, from 12-15 June 2022.

Key Points: 
  • The data is the subject of two poster presentations at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO), held in Hamburg, Germany, from 12-15 June 2022.
  • This builds on work previously presented at the American Association of Cancer Research (AACR) Annual Meeting in April 2022.
  • While the primary focus of the ISPNO presentation concerns animal models of the disease, two clinical case studies are also reported.
  • Importantly, these data underpin the ongoing phase II clinical trial testing the safety and efficacy of paxalisib and ONC201 in DIPG.

Ex MoneySuperMarket Group exec joins UK's leading online learning platform to disrupt edtech sector

Retrieved on: 
Tuesday, February 1, 2022
Partnership, DMG Media, CEO, FTSE, MoneySavingExpert.com, Student, Face, FutureLearn, Education, Population, Digital, Management, Tutoring

LONDON, Feb. 1, 2022 /PRNewswire/ -- Andy Hancock has been appointed as Chief Executive Officer of leading online learning platform FutureLearn.com, in order to continue driving the company forwards on its mission to transform access to education and scale its position as a global leader in edtech.

Key Points: 
  • Hancock brings extensive experience of scaling purpose-led consumer brands including MoneySavingExpert, DMG Media and most recently in his role as Chief Operating Officer at MoneySuperMarket Group PLC, a FTSE 250 company with the mission to help households save money.
  • He has a proven record of leading the digital transformation of content and marketplace businesses, helping them leverage data to grow across new sectors, markets and audiences.
  • We know the face of the modern day student has changed for good following the pandemic.
  • We also know that digital will play an increasingly central role in the evolution of the education sector and how it goes about reaching an ever more diverse student population.

PNOC Study in Childhood Brain Cancer Enrols First Patient

Retrieved on: 
Thursday, November 11, 2021
University, Brain, Chad, Associate, UCSF, KZIA, Neurosurgery, VEGFR3, Leadership, RUN, NASDAQ, Hospital, Disease, Doctor of Philosophy, Department, Glioma, GBM, Hunter Medical Research Institute, University of California, San Francisco, Radiation, Research, Pharmacotherapy, Multimedia, DMG Media, HIV disease progression rates, Principal, Department of Neurology, Xuanwu hospital, ONC201, PI3K, Twitter, Panobinostat, Pediatrics, University of Zurich, Molecular biology, Glioblastoma, US, Boston Children's Hospital, Diffuse intrinsic pontine glioma, Diagnosis, ASX, Survival, Patient, HMRI, PNOC, FDA, University of Hamburg, Orphan, Pharmaceutical industry, Medical imaging, Management, Medicine

PNOC022 includes Kazia's investigational drug, paxalisib among the experimental arms and is expected to provide valuable data on the potential use of the drug in this highly aggressive form of childhood brain cancer.

Key Points: 
  • PNOC022 includes Kazia's investigational drug, paxalisib among the experimental arms and is expected to provide valuable data on the potential use of the drug in this highly aggressive form of childhood brain cancer.
  • Diffuse intrinsic pontine glioma (DIPG) is the most common of a group of childhood brain cancers known as diffuse midline gliomas (DMGs).
  • The PNOC022 study is sponsored by the Pacific Pediatric Neuro-Oncology Consortium (PNOC), an international consortium focused on the development of new therapies for brain cancer.
  • The lead investigator, Professor Sabine Mueller, is a board-certified neurologist and paediatric neuro-oncologist whose research focuses on novel therapies in childhood brain cancer.

Acquisition of New Scientist

Retrieved on: 
Wednesday, March 3, 2021
Daily Mail and General Trust, Companies of the United Kingdom, I, DMG Media, Economy of the United Kingdom, New Scientist, Magazines

DMGT announces that dmg media, its Consumer Media business, has acquired New Scientist, one of the world's leading science publishing titles, from a consortium of individual investors led by Sir Bernard Gray, for 70m cash consideration.

Key Points: 
  • DMGT announces that dmg media, its Consumer Media business, has acquired New Scientist, one of the world's leading science publishing titles, from a consortium of individual investors led by Sir Bernard Gray, for 70m cash consideration.
  • New Scientist has a large and growing international readership, with a weekly circulation of approximately 120,000, of which just over half are UK-based.
  • Lord Rothermere, Chairman of DMGT, said: "New Scientist is a world-renowned publication loved by its readers, and we are both thrilled and proud to welcome it to the DMGT family.
  • Paul Zwillenberg, DMGT CEO, added: "The acquisition of New Scientist marks an exciting new addition to the DMGT portfolio and reflects our disciplined approach to acquisitions.